Atara Biotherapeutics, Inc. (ATRA) dividends
ATRA on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Atara Biotherapeutics, Inc. dividend: key facts
Own Atara Biotherapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next ATRA dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Atara Biotherapeutics says cash sufficient to fund operations into mid-202711 Nov 2026 · TheFly
The company stats: âOperating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 20...
- Atara Biotherapeutics reports Q3 EPS (15c), consensus (22c)11 Nov 2026 · TheFly
Reports Q3 revenue $1.2M, consensus $0.5M. âThe resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a...
- Atara Biotherapeutics files $200M mixed securities shelf11 Nov 2026 · TheFly
17:01 EST Atara Biotherapeutics (ATRA) files $200M mixed securities shelf
- Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress11 Nov 2026 · Business Wire
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
- Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel17 Oct 2026 · TheFly
Atara Biotherapeutics (ATRA) announced that its partner, Pierre Fabre Pharmaceuticals, PFP, has received acceptance by the U.S. Food and Drug Administration, FDA, of the Biologics License Application,...
- Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration17 Oct 2026 · Business Wire
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
- Atara reports resubmission of tabelecleucel BLA to FDA3 Oct 2026 · TheFly
Atara Biotherapeutics (ATRA) provided an update that its partner, Pierre Fabre Pharmaceuticals, has resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration...
- Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration3 Oct 2026 · Business Wire
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Insufficient verified data for a financial-health score
Dividend data and price last updated 17 Nov 2026.